These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38349311)

  • 61. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
    Pang N; Shi J; Qin L; Chen A; Tang Y; Yang H; Huang Y; Wu Q; Li X; He B; Li T; Liang B; Zhang J; Cao B; Liu M; Feng Y; Ye X; Chen X; Wang L; Tian Y; Li H; Li J; Hu H; He J; Hu Y; Zhi C; Tang Z; Gong Y; Xu F; Xu L; Fan W; Zhao M; Chen D; Lian H; Yang L; Li P; Zhang Z
    J Hematol Oncol; 2021 Jul; 14(1):118. PubMed ID: 34325726
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability.
    Hu JF; Wang ZW; Liao CY; Chen ZW; Kang FP; Lin CF; Lin TS; Huang L; Tian YF; Chen S
    Front Immunol; 2022; 13():958960. PubMed ID: 35990619
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Challenges of Anti-Mesothelin CAR-T-Cell Therapy.
    Zhai X; Mao L; Wu M; Liu J; Yu S
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900151
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Amatuximab and novel agents targeting mesothelin for solid tumors.
    Baldo P; Cecco S
    Onco Targets Ther; 2017; 10():5337-5353. PubMed ID: 29184420
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth.
    Yang P; Cao X; Cai H; Feng P; Chen X; Zhu Y; Yang Y; An W; Yang Y; Jie J
    Cell Immunol; 2021 Feb; 360():104262. PubMed ID: 33373818
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
    Melaiu O; Stebbing J; Lombardo Y; Bracci E; Uehara N; Bonotti A; Cristaudo A; Foddis R; Mutti L; Barale R; Gemignani F; Giamas G; Landi S
    PLoS One; 2014; 9(1):e85935. PubMed ID: 24465798
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
    Ko AH; Jordan AC; Tooker E; Lacey SF; Chang RB; Li Y; Venook AP; Tempero M; Damon L; Fong L; O'Hara MH; Levine BL; Melenhorst JJ; Plesa G; June CH; Beatty GL
    Mol Ther; 2020 Nov; 28(11):2367-2378. PubMed ID: 32730744
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment.
    Chen Q; Sun Y; Li H
    Discov Oncol; 2024 Jul; 15(1):289. PubMed ID: 39023820
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer.
    Batchu RB; Gruzdyn OV; Tavva PS; Kolli BK; Dachepalli R; Weaver DW; Gruber SA
    Surgery; 2019 Oct; 166(4):503-508. PubMed ID: 31416604
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation.
    Chen YL; Chang MC; Chiang YC; Lin HW; Sun NY; Chen CA; Sun WZ; Cheng WF
    Cancer Lett; 2018 Jul; 425():152-163. PubMed ID: 29596890
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
    Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
    J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer.
    Makita Y; Kunii N; Sakurai D; Ihara F; Motohashi S; Suzuki A; Nakayama T; Okamoto Y
    BMC Cancer; 2018 Dec; 18(1):1254. PubMed ID: 30558663
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin.
    Chakraborty A; Onda M; O'Shea T; Wei J; Liu X; Bera TK; Pastan I
    Mol Cancer Ther; 2024 Jun; ():OF1-OF10. PubMed ID: 38853444
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer.
    Tarannum M; Dinh K; Vergara J; Birch G; Abdulhamid YZ; Kaplan IE; Ay O; Maia A; Beaver O; Sheffer M; Shapiro R; Ali AK; Dong H; Ham JD; Bobilev E; James S; Cameron AB; Nguyen QD; Ganapathy S; Chayawatto C; Koreth J; Paweletz CP; Gokhale PC; Barbie DA; Matulonis UA; Soiffer RJ; Ritz J; Porter RL; Chen J; Romee R
    Sci Adv; 2024 Jul; 10(28):eadn0881. PubMed ID: 38996027
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies.
    Briolay T; Fresquet J; Meyer D; Kerfelec B; Chames P; Ishow E; Blanquart C
    Int J Nanomedicine; 2024; 19():633-650. PubMed ID: 38269255
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
    Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
    J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
    Lanitis E; Poussin M; Hagemann IS; Coukos G; Sandaltzopoulos R; Scholler N; Powell DJ
    Mol Ther; 2012 Mar; 20(3):633-43. PubMed ID: 22127019
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment.
    Wang Y; Fang X; Li M; Ye J; Zhao S; Yu L; Wang J; Wang Y; Yan Z
    Cancer Genet; 2022 Nov; 268-269():103-110. PubMed ID: 36288641
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
    Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
    Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.